TY - JOUR
T1 - The influence of implantation techniques on lesion oriented-outcomes in Absorb BVS and Xience EES lesions treated in routine clinical practice at complete three year follow-up: AIDA trial QCA substudy
AU - Tijssen, Ruben Y. G.
AU - Kerkmeijer, Laura S. M.
AU - Takahashi, Kuniaki
AU - Kogame, Norihiro
AU - Katagiri, Yuki
AU - Kraak, Robin P.
AU - Chichareon, Ply
AU - Modolo, Rodrigo
AU - Asano, Taku
AU - Nassif, Martina
AU - Kalkman, Deborah N.
AU - Sotomi, Yohei
AU - Collet, Carlos
AU - Hofma, Sjoerd H.
AU - van der Schaaf, Rene J.
AU - Arkenbout, E. Karin
AU - Weevers, Auke P. J. D.
AU - Piek, Jan J.
AU - Tijssen, Jan G. P.
AU - Henriques, Jose P.
AU - de Winter, Robbert J.
AU - Onuma, Yoshinobu
AU - Serruys, Patrick W.
AU - Wykrzykowska, Joanna J.
PY - 2020/4/1
Y1 - 2020/4/1
N2 - It has been hypothesized that dedicated optimized Absorb BVS implantation techniques might mitigate the risk of adverse events such as target vessel failure and device thrombosis. In this explorative AIDA trial QCA substudy, we sought to investigate the influence of implantation techniques on lesion-oriented outcomes in both the Absorb BVS and Xience EES arm at complete 3-year follow-up. The current analysis includes 2152 study lesions treated with at least one study device, of which the baseline angiogram was suited for offline QCA analysis, including Dmax analysis. The lesion-oriented composite outcome (LOCE) of this analysis was a composite of definite device thrombosis, target lesion revascularization and target-vessel myocardial infarction. In Absorb BVS, the Lesion-oriented composite endpoint (LOCE) occurred numerically less in correctly QCA sized vessels when compared to incorrectly sized vessels 8.5% (58/696) versus 11.1% (39/358), p = 0.151. In Xience EES, LOCE had occurred more frequently in incorrectly sized devices according to device diameter/RVD matching; 2.2% (4/187) in correctly sized devices versus 7.1% (63/911) in incorrectly sized devices (p = 0.014). In this AIDA trial QCA substudy, rates of LOCE were significantly lower in Xience EES treated lesions in which devices were correctly sized according to the definitions of device diameter/RVD matching.
AB - It has been hypothesized that dedicated optimized Absorb BVS implantation techniques might mitigate the risk of adverse events such as target vessel failure and device thrombosis. In this explorative AIDA trial QCA substudy, we sought to investigate the influence of implantation techniques on lesion-oriented outcomes in both the Absorb BVS and Xience EES arm at complete 3-year follow-up. The current analysis includes 2152 study lesions treated with at least one study device, of which the baseline angiogram was suited for offline QCA analysis, including Dmax analysis. The lesion-oriented composite outcome (LOCE) of this analysis was a composite of definite device thrombosis, target lesion revascularization and target-vessel myocardial infarction. In Absorb BVS, the Lesion-oriented composite endpoint (LOCE) occurred numerically less in correctly QCA sized vessels when compared to incorrectly sized vessels 8.5% (58/696) versus 11.1% (39/358), p = 0.151. In Xience EES, LOCE had occurred more frequently in incorrectly sized devices according to device diameter/RVD matching; 2.2% (4/187) in correctly sized devices versus 7.1% (63/911) in incorrectly sized devices (p = 0.014). In this AIDA trial QCA substudy, rates of LOCE were significantly lower in Xience EES treated lesions in which devices were correctly sized according to the definitions of device diameter/RVD matching.
KW - Bioresorbable scaffolds
KW - Drug eluting stents
KW - Quantitative coronary angiography
UR - http://www.scopus.com/inward/record.url?scp=85077294664&partnerID=8YFLogxK
U2 - https://doi.org/10.1007/s10554-019-01756-w
DO - https://doi.org/10.1007/s10554-019-01756-w
M3 - Article
C2 - 31898006
SN - 1569-5794
VL - 36
SP - 565
EP - 575
JO - international journal of cardiovascular imaging
JF - international journal of cardiovascular imaging
IS - 4
ER -